Skip to main content

Table 2 Prevalence of pfmdr1 184 polymorphisms in pre-treatment and post-treatment samples stratified by treatment arms

From: Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018

pfmdr1 Polymorphism

AL arm

ASAQ arm

Pre-treatment

Post-treatment

p value*

Pre-treatment

Post-treatment

p value*

n (%)

n (%)

 

n (%)

n (%)

 

 pfmdr1 codon 184

n = 79

n = 46

 

n = 30

n = 2

 

 Y184

30 (38.0)

12 (26.1)

Ref

12 (40.0)

0 (0)

Ref

 184Y/F

15 (10.0)

16 (34.8)

0.054

9 (30.0)

1 (50.0)

0.454

 184F

34 (43.0)

18 (39.1)

0.657

9 (30.0)

1 (50.0)

0.454

 pfmdr1 haplotypesa

n = 79

n = 46

 

n = 30

n = 2

 

 NYD

45 (57.0)

28 (60.9)

Ref

21 (70.0)

1 (50.0)

Ref

 NFD

49 (62.0)

34 (73.9)

0.746

18 (60.0)

2 (100)

0.597

  1. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine
  2. *Statistical significance in risk of recurrent infection (reinfection or recrudescence) was determined by Fisher’s exact test; three post-treatment samples (two in the AL arm and one in the ASAQ arm) failed to amplify at one or more loci and are not included in corresponding single nucleotide polymorphism and haplotype counts
  3. aHaplotype percentages may not sum to 100% because all possible haplotypes from mixed infections (both wild type and mutants) were included in the construction of haplotypes